Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Prepares For Advent Of SPC Manufacturing Waiver

Executive Summary

As the generics and biosimilars industries prepare for the European SPC manufacturing waiver to come into effect on 1 July, Generics Bulletin traces the history of the mechanism from early industry lobbying efforts to its ultimate entry into force.

You may also be interested in...



Procurement Must Look Beyond Price To Ensure Supply Chain Security

A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

Industry Laments UK Change To SPC Waiver Approach

Changes to how the UK plans to implement the SPC manufacturing waiver after it separates itself fully from the EU following the current Brexit transition period have been criticized by the generics industry, while originators have welcomed the move.

IGBA Urges Balance In EU-Australia Trade Deal

International off-patent industry body the IGBA has urged Australia’s government to “hold firm” against intellectual-property proposals made by the European Commission as part of negotiations over an Australia-EU trade deal. The organization believes the EU proposals would negatively impact access to generics and biosimilars in Australia.

Related Content

Topics

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel